重组人表皮生长因子治疗小儿手足口病口腔溃疡的疗效观察

Curative Effect Observation of Recombinant Human Epidermal Growth Factor in Treatment of Oral Ulcer in Children with Hand-Foot-Mouth Disease

目的:探讨重组人表皮生长因子(rh EGF)治疗小儿手足口病口腔溃疡的疗效。方法:将100例手足口病并发口腔溃疡患儿采用随机数字表法分为对照组和治疗组各50例。在全身治疗的基础上,对照组应用维生素B2调配鱼肝油于口腔溃疡处局部涂药,治疗组在溃疡创面喷洒重组人表皮生长因子,每日早、中、晚饭后及睡前各1次,每次2喷。比较两组手足口病及口腔溃疡症状的疗效,观察两组进食改善情况、溃疡愈合时间和药物不良反应发生情况。结果:治疗后两组总有效率比较差异无统计学意义(P>0.05);治疗组口腔溃疡总有效率(90.0%)显著高于对照组(58.0%),差异有统计学意义(P<0.05);治疗组患儿进食改善时间和口腔溃疡愈合时间均显著短于对照组,差异有统计学意义(P<0.05)。结论:重组人表皮生长因子喷雾剂治疗儿童手足口病口腔溃疡,能有效加快口腔溃疡愈合,缓解患儿痛苦,无明显不良反应,值得临床推广应用。

Objective： To discuss the curative effect of recombinant human epidermal growth factor （rhEGF） in treatment of oral ulcer in children with hand-foot-mouth disease. Methods： One hundred children with hand-foot-mouth disease complicated with oral ulcer were randomly divided into control group and treatment group, 50 cases in each group. Based on the systemic treatment, the control group was given vitamin B2 deployment cod-liver oil, the treatment group was given rhEGF spray, after breakfast, lunch, dinner and before bed each time, every time two jet spray. Respectively compared the efficacy of hand-font-mouth disease and oral ulcer symptoms of the two groups. The time of eat better and ulcer healing, adverse drug reactions were observed in both two groups. Results： After treatment, the total efficiency of hand-foot-mouth disease has no significant difference in two groups （ P〉0.05 ）. In treatment group, the total efficiency rate of oral ulcer （ 90.0% ） was significantly higher than that of the control group （ 58.0% ）, the difference was statistically significant （ P〈0.05 ）. The time of eating better and ulcer healing in treatment group were significantly shorter than those in the control group, the differences were statistically significant （P〈0.05）. Conclusion： The process of rhEGF spray in the treatment of children with hand-foot-mouth disease complicated with oral ulcer, can effectively accelerate the oral ulcer healing, improve eating, relieve pain of children, have no significant adverse reactions, is worth the clinical promotion.